What skin lesions can develop in a patient receiving Remicade (infliximab) and what is the recommended assessment and management?

Remicade Skin Lesions: Assessment and Management

Patients receiving Remicade (infliximab) commonly develop paradoxical skin lesions—most frequently psoriasiform eruptions and eczematous lesions—but these rarely require discontinuation of therapy and can typically be managed with topical treatments while continuing infliximab. 1

Types of Skin Lesions Associated with Remicade

The most common skin manifestations include:

• Psoriasiform eruptions (30.6% of skin lesions) - red scaly patches or raised bumps filled with pus 2
• Eczema (23.5%) 2
• Xerosis cutis (dry skin, 10.6%) 2
• Palmoplantar pustulosis (5.3%) 2
• Frank psoriasis (3.8%) 2
• Other immune-mediated lesions including granuloma annulare, skin vasculitis, alopecia areata, and lichenoid eruptions 3

Typical Distribution Patterns

Lesions characteristically appear at:

• Flexural regions (elbows, knees, skin folds)
• Genitalia
• Scalp (especially psoriasiform lesions)
• Palms and soles (pustular variants) 2

Clinical Assessment

Key Features to Identify

Timing: Skin lesions typically develop between 3 to 36 months after initiating infliximab therapy (median 20 months), though they can occur as early as the 15th week 3, 4

Prevalence: Approximately 29% of patients on anti-TNF therapy develop skin lesions, with slightly higher rates in women (31%) versus men (26%) 2

Important caveat: The FDA label explicitly warns that "some people receiving REMICADE had new psoriasis or worsening of psoriasis they already had" 1. This paradoxical effect occurs despite infliximab being an effective treatment for psoriasis itself 5.

Distinguish from Other Conditions

Rule out:

• Infectious causes (bacterial, fungal, viral)
• Infusion reactions (occur within 2 hours of infusion with fever, chills, rash, itching) 1
• Delayed allergic reactions (3-12 days post-infusion with fever, rash, headache, muscle/joint pain) 1
• Lupus-like syndrome (rash on cheeks/arms worsening with sun exposure, chest pain, joint pain) 1

Management Algorithm

Step 1: Assess Severity and Impact

• Document extent, distribution, and symptoms
• Evaluate impact on quality of life
• Check for signs of infection

Step 2: Initial Management (Continue Infliximab)

Critical point: Only 11% of patients require discontinuation of infliximab due to skin lesions 2. The evidence strongly supports continuing therapy with adjunctive dermatologic treatment.

First-line approach:

• Topical corticosteroids (high-potency for body, lower potency for face/genitals)
• Emollients for xerosis
• Vitamin D analogues can be added for psoriasiform lesions 5

Step 3: Dermatology Referral

Early referral to dermatology is recommended for:

• Moderate to severe lesions
• Lesions not responding to initial topical therapy within 2-4 weeks
• Uncertain diagnosis
• Patient distress affecting quality of life 2

Step 4: Advanced Dermatologic Management (While Continuing Infliximab)

For refractory cases, dermatologists may add:

• Systemic therapies (e.g., cyclosporine for severe psoriasiform eruptions) 4
• Phototherapy (narrowband UVB)
• Standard psoriasis treatments if frank psoriasis develops

Evidence from IBD studies: 89% of patients with infliximab-induced skin lesions were successfully managed without stopping therapy 2. Among those who continued infliximab with adjunctive skin treatments, 90% achieved complete resolution 6.

Step 5: Consider Discontinuation Only If:

• Extensive, severe lesions unresponsive to aggressive dermatologic management
• Significant impact on quality of life despite treatment
• Patient preference after shared decision-making

If discontinuation is necessary: Skin lesions typically resolve, though this is not guaranteed. In one study, only 1 of 4 patients had regression after stopping the TNF inhibitor 6.

Monitoring Strategy

• Structured skin screening at each infusion visit by nursing staff 7
• Document new lesions, changes in existing lesions
• Assess for warning signs of serious reactions (see FDA warnings above)
• Monitor response to topical treatments

Common Pitfalls to Avoid

1. Don't automatically discontinue infliximab when skin lesions appear—this is rarely necessary and may compromise control of the underlying inflammatory condition 2

2. Don't confuse paradoxical psoriasiform eruptions with treatment failure—these are immune-mediated adverse effects, not disease progression

3. Don't delay dermatology referral for moderate-severe lesions—early specialist involvement improves outcomes while maintaining infliximab therapy 2

4. Don't ignore the patient's underlying disease activity—the risk-benefit analysis must prioritize control of Crohn's disease, ulcerative colitis, or rheumatologic condition over manageable skin manifestations

Special Considerations

Crohn's disease patients have the highest association with skin manifestations (nearly 80% of affected patients), so heightened surveillance is warranted in this population 7.

Dose relationship: Skin lesions are not clearly dose-dependent; similar cumulative doses and trough levels occur in patients with and without lesions 2. However, one study noted increased risk with dose escalation 6.